Protheragen Launches Specialized Pharmacokinetic Service Platform for Anti-Obesity Therapeutics

Protheragen, a contract research organization (CRO) focused on preclinical drug development services, has launched a service offering focused on preclinical in vivo and in vitro pharmacokinetic (PK) evaluation of anti-obesity therapeutic drugs. According to the WHO, more than one billion people worldwide are living with obesity, creating an urgent need for safe and effective new therapeutic drugs. The integrated service offering provides biotech and pharma partners with key ADME data to reduce risk and accelerate development of next-generation anti-obesity therapeutics.
Protheragen's anti-obesity therapeutic PK study offering is a specialized service, compared to conventional PK evaluations, that takes into account the fundamental changes that the state of obesity imposes on human physiology (i.e. changes in gastric emptying, metabolic organ perfusion, and metabolic rate). As a result of these changes, the behavior of drugs in the body is also altered, making conventional PK assessments insufficient. The integrated, one-stop research program undertaken by Protheragen is designed to understand drug behavior and address challenges associated with drug fate and elimination.
Protheragen's anti-obesity therapeutic PK study offering is a specialized service, compared to conventional PK evaluations, that takes into account the fundamental changes that the state of obesity imposes on human physiology (i.e. changes in gastric emptying, metabolic organ perfusion, and metabolic rate). As a result of these changes, the behavior of drugs in the body is also altered, making conventional PK assessments insufficient. The integrated, one-stop research program undertaken by Protheragen is designed to understand drug behavior and address challenges associated with drug fate and elimination.
Beyond PK analysis, Protheragen offers comprehensive services for therapeutic modalities that include small molecules, gene therapies, cell therapies, antibody therapies, tissue engineering, and nanotherapies. Within small molecule therapies, Protheragen performs natural products and compound screens on the melanocortin-4 receptor (MC4R), leptin receptor (LepR), and adiponectin receptor (AdipoR) pathways. For advanced biologics, Protheragen employs gene editing to design tailored gene therapies, uses phage display and hybridoma technologies for antibody design, and evaluates nanotechnology for weight loss. Protheragen can assist partners from target identification to IND-enabling.